J&J contractor plans to resume COVID-19 vaccine production at Baltimore plant - WSJ

Reuters2021-07-29

July 28 (Reuters) - Johnson & Johnson contractor Emergent Biosolutions Inc plans to resume COVID-19 vaccine production at its Baltimore plant after getting approval from the U.S. Food and Drug Administration (FDA), the Wall Street Journal reported late on Wednesday, citing a statement from the company and a FDA letter.

Production of J&J's COVID-19 vaccine at the Baltimore site was halted by U.S. authorities in April following a discovery that ingredients from AstraZeneca's COVID-19 vaccine, also being produced at the plant at that time, contaminated a batch of J&J's vaccines.

J&J, Emergent and the FDA did not immediately respond to Reuters requests for comment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • AnaiAnai
    2021-07-29
    AnaiAnai
    good. at least more vaccines are available. More people will be vaccinated earlier and can go back to normalcy sooner.
  • June陈
    2021-07-29
    June陈
    ....
  • Bptan1973
    2021-07-29
    Bptan1973
    Good news 
  • MoneyCum
    2021-07-29
    MoneyCum
    Yeah
  • BWMoxx
    2021-07-29
    BWMoxx
    Ohhhh
  • geraldzhang
    2021-07-29
    geraldzhang
    more people need to get vaccinated before the world can open up
Leave a comment
10